By: IPP Bureau
Last updated : March 17, 2022 6:55 pm
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
On the occasion of National Immunisation Day and in an effort to support the Government’s ongoing efforts to protect our country against COVID-19, Biological E. is geared to facilitate the first phase of the vaccination drive for the 12 to 15 years’ Indian population through its vaccine CORBEVAXTM. Biological E. Limited collaborated with the Texas Children’s Hospital and the Baylor College to develop Corbevax vaccine, a company release said.
The pricing of Corbevax in the private market will be Rs. 990 inclusive of all taxes and vaccine administration charges.
Corbevax is a recombinant protein subunit vaccine against the novel coronavirus and has been given emergency use authorisation (EUA) for children aged 12-18 years and adults from 18-80 yrs. Corbevax is administered through intramuscular route with two doses scheduled 28 days apart and is stored at 2 to 8 degrees Celsius.
Biological E limited had begun the manufacturing Corbevax for stockpiling after approval, based on the favourable clinical evidence and review by experts. Multiple Biological E. Limited facilities in Hyderabad are currently producing and will continue to produce the vaccine. The group will leverage its robust pan India presence and partner with the State Governments, hospitals and Medical institutions to leave no stone unturned in facilitating the uninterrupted supply of “Corbevax”: COVID-19 vaccine. To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India.
On the occasion, Mahima Datla, Managing Director, Biological E. Limited said, “As the entire country awaits the new phase of immunisation drive for the 12 to 15 years, we at Biological E. Limited are privileged to support the Indian Government in this valiant exercise through our Corbevax vaccine. We are grateful to our Prime Minister, Shri Narendra Modi for giving us an opportunity to join the fight against the deadly coronavirus. It’s been a significant development for us to extend our vaccine reach to children aged 12-15 years. Not only will this allow them to resume their daily lives, but it will also lower the parents’ concerns as they see their children resuming academic activities in person.”
She further added, “Biological E Limited has achieved a capacity to produce 100+ million doses per month in order to ensure adequate supply and we are able to respond to any increasing demand too, should the need arise.”
The pricing of Corbevax in the private market will be Rs. 990 inclusive of all taxes and vaccine administration charges.